Finfer SR, Cohen J. Severe traumatic brain injury. Resuscitation. 2001;48(1):77–90.
Hsiang J, Marshall LF. Head injury. In: Swash M, editor. Outcomes in neurological and neurosurgical disorders. New York: Cambridge University Press; 1998. p. 157–80.
McAllister TW. Neurobiological consequences of traumatic brain injury. Dialogues Clin Neurosci. 2011;13(3):287–300.
Finnie JW, Blumbergs PC. Traumatic brain injury. Vet Pathol. 2002;39(6):679–89.
Smith DH, Meaney DF, Shull WH. Diffuse axonal injury in head trauma. J Head Trauma Rehabil. 2003;18(4):307–16.
De Girolami U, Frosch MP, Anthony DC. The central nervous system. In: Cotran CR, Kumar V, Collins T, editors. Robbins pathological basis of disease. Philadelphia: W. B. Saunders Company; 1999. p. 1293–357.
McIntosh TK, Smith DH, Garde E. Therapeutic approaches for the prevention of secondary brain injury. Eur J Anaesthesiol. 1996;13(3):291–309.
Bullock R. Injury and cell function. In: Reilly P, Bullock R, editors. Head injury: pathophysiology and management of severe closed injury. London: Chapman and Hall; 1997. p. 121–41.
Povlishock JT, Christman CW. The pathophysiology of traumatic brain injury. In: Salzman SK, Faden AI, editors. The neurobiology of central nervous system trauma. New York: Oxford University Press; 1994. p. 109–20.
Birch NJ. Magnesium and the cell. London: Academic; 1993.
Ebel H, Gunther T. Magnesium metabolism: a review. J Clin Chem Clin Biochem. 1980;18(5):257–70.
Terasaki M, Rubin H. Evidence that intracellular magnesium is present in cells at a regulatory concentration for protein synthesis. Proc Natl Acad Sci U S A. 1985;82(21):7324–6.
Bara M, Guiet-Bara A. Potassium, magnesium and membranes. Review of present status and new findings. Magnesium. 1984;3(4–6):215–25.
Marcoux J, McArthur DA, Miller C, et al. Persistent metabolic crisis as measured by elevated cerebral microdialysis lactate-pyruvate ratio predicts chronic frontal lobe brain atrophy after traumatic brain injury. Crit Care Med. 2008;36(10):2871–7.
Vink R, McIntosh TK, Yamakami I, Faden AI. 31P NMR characterization of graded traumatic brain injury in rats. Magn Reson Med. 1988;6(1):37–48.
Tavazzi B, Signoretti S, Lazzarino G, et al. Cerebral oxidative stress and depression of energy metabolism correlate with severity of diffuse brain injury in rats. Neurosurgery. 2005;56(3):582–9.
Verweij BH, Muizelaar JP, Vinas FC, Peterson PL, Xiong Y, Lee CP. Improvement in mitochondrial dysfunction as a new surrogate efficiency measure for preclinical trials: dose–response and time -window profiles for administration of the calcium channel blocker Ziconotide in experimental brain injury. J Neurosurg. 2000;93:829–34.
Vink R, Cernak I. Regulation of intracellular free magnesium in central nervous system injury. Front Biosci. 2000;5:D656–65.
Lemasters JJ, Theruvath TP, Zhong Z, Nieminen AL. Mitochondrial calcium and the permeability transition in cell death. Biochim Biophys Acta. 2009;1787(11):1395–401.
Sherwood L. Human physiology: from cells to systems. Belmont: Wadsworth Publishing Company; 1997.
Hovda DA, Becker DP, Katayama Y. Secondary injury and acidosis. J Neurotrauma. 1992;9 Suppl 1:S47–60.
McIntosh TK, Vink R, Soares H, Hayes R, Simon R. Effect of noncompetitive blockade of N-methyl-D-aspartate receptors on the neurochemical sequelae of experimental brain injury. J Neurochem. 1990;55(4):1170–9.
Mendelow AD, Crawford PJ. Primary and secondary brain injury. In: Reilly P, Bullock R, editors. Head injury: pathophysiology and management of severe closed injury. London: Chapman and Hall; 1997. p. 72–88.
Scheff SW, Sullivan PG. Cyclosporin A significantly ameliorates cortical damage following experimental traumatic brain injury in rodents. J Neurotrauma. 1999;16(9):783–92.
Iseri LT, French JH. Magnesium: nature’s physiologic calcium blocker. Am Heart J. 1984;108(1):188–93.
Hallak M, Berman RF, Irtenkauf SM, Janusz CA, Cotton DB. Magnesium sulfate treatment decreases N-methyl-D-aspartate receptor binding in the rat brain: an autoradiographic study. J Soc Gynecol Investig. 1994;1(1):25–30.
Brocard JB. Glutamate induced increases in intracellular free Mg(2+) in cultured cortical neurons. Neuron. 1993;11(4):751–7.
Choi DW. Excitotoxic cell death. J Neurobiol. 1992;23(9):1261–76.
Mayer ML, Westbrook GL, Guthrie PB. Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature. 1984;309(5965):261–3.
Ascher P. Measuring and controlling the extracellular glycine concentration at the NMDA receptor level. Adv Exp Med Biol. 1990;268:13–6.
Faden AI, Demediuk P, Panter SS, Vink R. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science. 1989;244(4906):798–800.
Zhang L, Rzigalinski BA, Ellis EF, Satin LS. Reduction of voltage-dependent Mg2+ blockade of NMDA current in mechanically injured neurons. Science. 1996;274(5294):1921–3.
Choi DW. Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. TINS. 1988;11(10):465–9.
Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab. 2001;21(1):2–14.
Globus MY, Alonso O, Dietrich WD, Busto R, Ginsberg MD. Glutamate release and free radical production following brain injury: effects of posttraumatic hypothermia. J Neurochem. 1995;65(4):1704–11.
Awasthi D, Church DF, Torbati D, Carey ME, Pryor WA. Oxidative stress following traumatic brain injury in rats. Surg Neurol. 1997;47(6):575–81.
Lewen A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma. 2000;17(10):871–90.
Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J Neurochem. 1997;68(1):255–64.
Mark RJ, Pang Z, Geddes JW, Uchida K, Mattson MP. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci. 1997;17(3):1046–54.
Weglicki WB, Phillips TM. Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis. Am J Physiol. 1992;263(3 Pt 2):R734–7.
Nimmo AJ, Cernak I, Heath DL, Hu X, Bennett CJ, Vink R. Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats. Neuropeptides. 2004;38(1):40–7.
Black PH. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun. 2002;16(6):622–53.
Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V. The tachykinin peptide family. Pharmacol Rev. 2002;54(2):285–322.
Donkin JJ, Nimmo AJ, Cernak I, Blumbergs PC, Vink R. Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury. J Cereb Blood Flow Metab. 2009;29(8):1388–98.
Turner RJ, Blumbergs PC, Sims NR, Helps SC, Rodgers KM, Vink R. Increased substance P immunoreactivity and edema formation following reversible ischemic stroke. Acta Neurochir Suppl. 2006;96:263–6.
Turner RJ, Helps SC, Thornton E, Vink R. A substance P antagonist improves outcome when administered 4 h after onset of ischaemic stroke. Brain Res. 2011;1393:84–90.
Vink R, Young A, Bennett CJ, et al. Neuropeptide release influences brain edema formation after diffuse traumatic brain injury. Acta Neurochir Suppl. 2003;86:257–60.
Donkin JJ, Turner RJ, Hassan I, Vink R. Substance P in traumatic brain injury. Prog Brain Res. 2007;161:97–109.
Malpuech-Brugere C, Nowacki W, Daveau M, et al. Inflammatory response following acute magnesium deficiency in the rat. Biochim Biophys Acta. 2000;1501(2–3):91–8.
Shogi T, Oono H, Nakagawa M, Miyamoto A, Ishiguro S, Nishio A. Effects of a low extracellular magnesium concentration and endotoxin on IL-1beta and TNF-alpha release from, and mRNA levels in, isolated rat alveolar macrophages. Magnes Res. 2002;15(3–4):147–52.
Hutchinson PJ, O’Connell MT, Rothwell NJ, et al. Inflammation in human brain injury: intracerebral concentrations of IL-1alpha, IL-1beta, and their endogenous inhibitor IL-1ra. J Neurotrauma. 2007;24(10):1545–57.
Morganti-Kossman MC, Lenzlinger PM, Hans V, et al. Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue. Mol Psychiatry. 1997;2(2):133–6.
Taupin V, Toulmond S, Serrano A, Benavides J, Zavala F. Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion. Influence of pre- and post-traumatic treatment with Ro5 4864, a peripheral-type (p site) benzodiazepine ligand. J Neuroimmunol. 1993;42(2):177–85.
Zhu HD, Martin R, Meloni B, et al. Magnesium sulfate fails to reduce infarct volume following transient focal cerebral ischemia in rats. Neurosci Res. 2004;49(3):347–53.
Molina-Holgado E, Ortiz S, Molina-Holgado F, Guaza C. Induction of COX-2 and PGE(2) biosynthesis by IL-1beta is mediated by PKC and mitogen-activated protein kinases in murine astrocytes. Br J Pharmacol. 2000;131(1):152–9.
Rothwell N. Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential. Brain Behav Immun. 2003;17(3):152–7.
Shohami E, Ginis I, Hallenbeck JM. Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev. 1999;10(2):119–30.
Kristian T, Siesjo BK. Calcium in ischemic cell death. Stroke. 1998;29(3):705–18.
Hicks RR, Smith DH, Lowenstein DH, Saint Marie R, McIntosh TK. Mild experimental brain injury in the rat induces cognitive deficits associated with regional neuronal loss in the hippocampus. J Neurotrauma. 1993;10(4):405–14.
Murasato Y, Harada Y, Ikeda M, Nakashima Y, Hayashida Y. Effect of magnesium deficiency on autonomic circulatory regulation in conscious rats. Hypertension. 1999;34(2):247–52.
Vink R, Nimmo AJ, Cernak I. An overview of new and novel pharmacotherapies for use in traumatic brain injury. Clin Exp Pharmacol Physiol. 2001;28(11):919–21.
Ravishankar S, Ashraf QM, Fritz K, Mishra OP, Delivoria-Papadopoulos M. Expression of Bax and Bcl-2 proteins during hypoxia in cerebral cortical neuronal nuclei of newborn piglets: effect of administration of magnesium sulfate. Brain Res. 2001;901(1–2):23–9.
Kowaltowski AJ, Netto LE, Vercesi AE. The thiol-specific antioxidant enzyme prevents mitochondrial permeability transition. Evidence for the participation of reactive oxygen species in this mechanism. J Biol Chem. 1998;273(21):12766–9.
Muir JK, Raghupathi R, Emery DL, Bareyre FM, McIntosh TK. Postinjury magnesium treatment attenuates traumatic brain injury-induced cortical induction of p53 mRNA in rats. Exp Neurol. 1999;159(2):584–93.
Raghupathi R, Graham DI, McIntosh TK. Apoptosis after traumatic brain injury. J Neurotrauma. 2000;17(10):927–38.
Dong GX, Singh DK, Dendle P, Prasad RM. Regional expression of Bcl-2 mRNA and mitochondrial cytochrome c release after experimental brain injury in the rat. Brain Res. 2001;903(1–2):45–52.
Vink R, McIntosh TK, Demediuk P, Faden AI. Decrease in total and free magnesium concentration following traumatic brain injury in rats. Biochem Biophys Res Commun. 1987;149(2):594–9.
Vink R, McIntosh TK, Demediuk P, Weiner MW, Faden AI. Decline in intracellular free Mg2+ is associated with irreversible tissue injury after brain trauma. J Biol Chem. 1988;263(2):757–61.
Vink R, Nechifor M, editors. Magnesium in the CNS. Adelaide: Adelaide University Press; 2011.
Cernak I, Savic VJ, Kotur J, Prokic V, Veljovic M, Grbovic D. Characterization of plasma magnesium concentration and oxidative stress following graded traumatic brain injury in humans. J Neurotrauma. 2000;17(1):53–68.
Heath DL, Vink R. Traumatic brain axonal injury produces sustained decline in intracellular free magnesium concentration. Brain Res. 1996;738(1):150–3.
Smith DH, Cecil KM, Meaney DF, et al. Magnetic resonance spectroscopy of diffuse brain trauma in the pig. J Neurotrauma. 1998;15(9):665–74.
Suzuki M, Nishina M, Endo M, et al. Decrease in cerebral free magnesium concentration following closed head injury and effects of VA-045 in rats. Gen Pharmacol. 1997;28(1):119–21.
McIntosh TK, Faden AI, Yamakami I, Vink R. Magnesium deficiency exacerbates and pretreatment improves outcome following traumatic brain injury in rats: 31P magnetic resonance spectroscopy and behavioral studies. J Neurotrauma. 1988;5(1):17–31.
Vink R, Heath DL, McIntosh TK. Acute and prolonged alterations in brain free magnesium following fluid percussion-induced brain trauma in rats. J Neurochem. 1996;66(6):2477–83.
Cook NL, Van Den Heuvel C, Vink R. Are the transient receptor potential melastatin (TRPM) channels important in magnesium homeostasis following traumatic brain injury? Magnes Res. 2009;22(4):225–34.
Heath DL, Vink R. Neuroprotective effects of MgSO4 and MgCl2 in closed head injury: a comparative phosphorus NMR study. J Neurotrauma. 1998;15(3):183–9.
Heath DL, Vink R. Improved motor outcome in response to magnesium therapy received up to 24 hours after traumatic diffuse axonal brain injury in rats. J Neurosurg. 1999;90(3):504–9.
Heath DL, Vink R. Concentration of brain free magnesium following severe brain injury correlates with neurologic motor outcome. J Clin Neurosci. 1999;6(6):505–9.
Heath DL, Vink R. Optimization of magnesium therapy after severe diffuse axonal brain injury in rats. J Pharmacol Exp Ther. 1999;288(3):1311–6.
Hoane MR, Barbay S, Barth TM. Large cortical lesions produce enduring forelimb placing deficits in un-treated rats and treatment with NMDA antagonists or anti-oxidant drugs induces behavioral recovery. Brain Res Bull. 2000;53(2):175–86.
McDonald JW, Silverstein FS, Johnston MV. Magnesium reduces N-methyl-D-aspartate (NMDA)-mediated brain injury in perinatal rats. Neurosci Lett. 1990;109(1–2):234–8.
McIntosh TK, Vink R, Yamakami I, Faden I. Magnesium protects against neurological deficit after brain injury. Brain Res. 1989;482:252–60.
Smith DH, Okiyama K, Gennarelli TA, McIntosh TK. Magnesium and ketamine attenuate cognitive dysfunction following experimental brain injury. Neurosci Lett. 1993;157(2):211–4.
Heath DL, Vink R. Magnesium sulphate improves neurologic outcome following severe closed head injury in rats. Neurosci Lett. 1997;228(3):175–8.
Hoane MR, Barth TM. The behavioral and anatomical effects of MgCl2 therapy in an electrolytic lesion model of cortical injury in the rat. Magnes Res. 2001;14(1–2):51–63.
Muir KW, Lees KR. A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Stroke. 1995;26(7):1183–8.
Muir KW, Lees KR. Dose optimization of intravenous magnesium sulfate after acute stroke. Stroke. 1998;29(5):918–23.
Saatman KE, Bareyre FM, Grady MS, McIntosh TK. Acute cytoskeletal alterations and cell death induced by experimental brain injury are attenuated by magnesium treatment and exacerbated by magnesium deficiency. J Neuropathol Exp Neurol. 2001;60(2):183–94.
Marinov MB, Harbaugh KS, Hoopes PJ, Pikus HJ, Harbaugh RE. Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia. J Neurosurg. 1996;85(1):117–24.
Schanne FA, Gupta RK, Stanton PK. 31P-NMR study of transient ischemia in rat hippocampal slices in vitro. Biochim Biophys Acta. 1993;1158(3):257–63.
Sirin BH, Coskun E, Yilik L, Ortac R, Sirin H, Tetik C. Neuroprotective effects of preischemia subcutaneous magnesium sulfate in transient cerebral ischemia. Eur J Cardiothorac Surg. 1998;14(1):82–8.
Duley L. Pre-eclampsia, eclampsia, and hypertension. Clin Evid (Online). 2011;2011.
Flather M, Pipilis A, Collins R, et al. Randomized controlled trial of oral captopril, of oral isosorbide mononitrate and of intravenous magnesium sulphate started early in acute myocardial infarction: safety and haemodynamic effects. ISIS-4 (Fourth International Study of Infarct Survival) Pilot Study Investigators. Eur Heart J. 1994;15(5):608–19.
Ma L, Liu WG, Zhang JM, Chen G, Fan J, Sheng HS. Magnesium sulphate in the management of patients with aneurysmal subarachnoid haemorrhage: a meta-analysis of prospective controlled trials. Brain Inj. 2010;24(5):730–5.
Gorelick PB, Ruland S. IMAGES and FAST-MAG: magnesium for acute ischaemic stroke. Lancet Neurol. 2004;3(6):330.
Muir KW, Lees KR, Ford I, Davis S. Magnesium for acute stroke (intravenous magnesium efficacy in Stroke trial): randomised controlled trial. Lancet. 2004;363(9407):439–45.
Temkin NR, Anderson GD, Winn HR, et al. Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial. Lancet Neurol. 2007;6:29–38.
Dhandapani SS, Gupta A, Vivekanandhan S, Sharma BS, Mahapatra AK. Randomized controlled trial of magnesium sulphate in severe closed traumatic brain injury. Ind J Neurotrauma. 2008;5:27–33.
Yang Y, Qiu L, Fayyaz A, Shuaib A. Survival and histological evaluation of therapeutic window of post-ischemia treatment with magnesium sulfate in embolic stroke model of rat. Neurosci Lett. 2000;285:119–22.
McKee JA, Brewer RP, Macy GE, et al. Analysis of the brain bioavailability of peripherally administered magnesium sulfate: a study in humans with acute brain injury undergoing prolonged induced hypermagnesemia. Crit Care Med. 2005;33(3):661–6.
Brewer RP, Parra A, Borel CO, Hopkins MB, Reynolds JD. Intravenous magnesium sulfate does not increase ventricular CSF ionized magnesium concentration of patients with intracranial hypertension. Clin Neuropharmacol. 2001;24(6):341–5.
Lee JH, Roy J, Sohn HM, et al. Magnesium in a polyethylene glycol formulation provides neuroprotection after unilateral cervical spinal cord injury. Spine. 2010;35(23):2041–8.
Meloni BP, Zhu H, Knuckey NW. Is magnesium neuroprotective following global and focal cerebral ischaemia? A review of published studies. Magnes Res. 2006;19(2):123–37.